Innocoll Announces Appointment of Anthony H. Wild Ph.D. to Chairman of the Board
ASHBURN, Va., June 17 /PRNewswire/ -- Innocoll Inc. today announced that its board of directors appointed Anthony H. Wild, Ph.D. to the post of chairman of the board, effective immediately. Dr. Wild succeeds Rolf Schmidt who will remain on the board after serving as chairman since the company's inception.
Dr. Wild has served as a director of the company since July 2008. He is a co-founder and General Partner of BOWS Pharmaceuticals AG, a Swiss drug-delivery technology company, and a member of the boards of directors of several privately-owned specialty pharmaceutical and biotechnology companies. He also chairs the board of advisors of Ferrer, Freeman and Co., a healthcare private equity firm. He is on the board of advisors of Celtic Therapeutics, a pharmaceutical venture fund and is an advisor to Golden Pond Healthcare Inc., a special acquisitions corporation.
Dr Wild was the Chairman of MedPointe Pharmaceuticals Inc., a privately-held specialty pharmaceutical company based in Somerset (NJ), until its acquisition by Meda AB of Sweden in 2007. He also served as CEO from 2001 until 2006.
Between 1995 and 2000, Dr Wild worked for the Warner-Lambert Company, of Morris Plains (NJ). Starting as President of Warner-Lambert's Parke-Davis (North America) unit, he was promoted to Executive Vice President and President of its global Pharmaceutical Sector in 1996. Before joining Warner-Lambert, Dr Wild spent 22 years with the Schering-Plough Corporation in various roles culminating as President of its Japanese operations.
Dr Wild graduated in 1968 from the University of York where he earned an honors degree in Chemistry. He also holds a Ph.D. degree in physical chemistry from the University of Cambridge (Churchill College).
Dr. Wild commented, "I am honored to take over from Rolf Schmidt as Chairman and would like to thank him for his vision in founding Innocoll and leading the Board up to this point. I am very pleased how far the company has come and am excited at our prospects in the coming months and years".
Rolf Schmidt noted, "I have known Dr. Wild for a number of years as a professional with just the skill set to help bring the growing pipeline of the company's products to market. His deep understanding of the industry is a special asset of significant value to the growth of our company. It is a privilege to work with Tony in this exciting period."
About Innocoll, Inc.
Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx® and Liquicoll®. Innocoll has licensed its US marketing rights to its lead product, CollaRx GENTAMICIN SURGICAL IMPLANT to Baxter Healthcare, a division of Baxter International Inc. (NYSE: BAX.) The product is currently in phase 3 development in the US for the prevention of surgical site infections. It is approved for sale in 49 countries in Europe, Latin America, Middle East, Africa and Asia. Other late stage pharmaceutical products in Innocoll's development pipeline include CollaRx Gentamicin Topical for the treatment and prevention of infected diabetic foot ulcers and CollaRx Bupivacaine Implant for the management of post-operative pain, both of which are currently in Phase 2 development. For more information, please visit www.innocollinc.com.
SOURCE Innocoll, Inc.